As a specialized, special and new enterprise in Beijing, InnoModels Biotechnology (Beijing) Co., Ltd. has been working in the field of humanized models of the immune system since its establishment, and has continuously promoted the research, development and application of related technologies. The humanized immune system model developed by the company has successfully rebuilt the human immune system in mice by transplanting human immune cells or precursor cells into mice, providing unprecedented experimental means for drug research and development, tumor immunotherapy and other fields.
The humanized immune system model of InnoModels has remarkable features. Firstly, it realizes the stable reconstruction of the immune system. Traditional animal models are often difficult to fully simulate the human immune system, resulting in large discrepancies between experimental results and clinical data. However, the modeling success rate of the biomimetic model has been improved from 50% to 87%, and the coefficient of variation within the group has also been greatly reduced, which makes the experimental results more reliable and stable.
Secondly, the model of InnoModels is able to reconstruct multiple immune cells. In previous models, only T-cells can be successfully reconstructed in mice. However, the model breaks through this limitation and can reconstruct a variety of immune cells, including T cells, B cells, NK cells, macrophages, DC cells, etc., thus more realistically simulating the complexity of the human immune system.

In addition, the number of immune cells reconstructed in the model of InnoModels Biotechnology can reach or approach the concentration of human immune cells. This means that the model can provide a more realistic environment for drug testing, enabling drugs to be evaluated under conditions closer to the actual human condition before entering clinical trials, thus improving the efficiency and success rate of drug development.
In order to meet the needs of different fields, InnoModels Biotechnology also provides customers with several sub-platforms. Among them, the iHuPBMC-T platform is designed for T-cell immunotherapy, which is able to simulate the behavior of human T-cells in the tumor microenvironment, providing strong support for T-cell immunotherapy research and development. In addition, InnoModels Biotechnology has also launched the PBMC-PDX Dual Derivative Model, which can be modeled using tumors and PBMCs originating from the same patient, making the experimental results closer to the clinical reality.
It is worth mentioning that InnoModels' PBMC-PDX model has successfully solved the major problems of tumor growth and PBMC antagonism and cycle matching in immune system tumor models, significantly improving the success rate of experiments and overcoming the problem of short drug delivery window due to graft-versus-host disease. This makes the model have higher application value in the development of tumor immunity drugs.
Overall, the humanized model of the immune system of InnoModels Biotechnology shows great potential in the fields of drug discovery and tumor immunotherapy due to its stability, multicellular reconstruction, and proximity to human body concentration. Meanwhile, the multiple sub-platforms it provides also meet the needs of different fields, providing scientists with richer and more efficient experimental means. It is believed that in the future, InnoModels Biotechnology will continue to make innovations and breakthroughs in the field of humanized models of the immune system, and make greater contributions to the cause of human health.